Search:
Tokushima UniversityGraduate School of Biomedical Sciences薬学域Pharmaceutical SciencePharmaceutical Life SciencesDepartment of Molecular Pharmacology
Tokushima UniversityResearch ClustersResearch Clusters (Registered)2104015 医療ビッグデータ解析を活用した治療の最適化およびドラッグリポジショニング研究
Tokushima UniversityFaculty of Pharmaceutical SciencesPharmaceutical Sciences医薬品探索学講座生命薬理学
Tokushima UniversityGraduate School of Pharmaceutical SciencesPharmaceutical Sciences
(Files for researchmap) [PDF manual] [Auto-propagate to researchmap]

Research

Personal Web Page

Field of Study

Pharmacology, Cellular Pharmacology, Molecular Pharmacology

Subject of Study

Gタンパク質共役型受容体情報伝達系の解明, プロスタノイド受容体と病態の解明

Book / Paper

Book:

1. Hiromichi Fujino :
2章 薬物作用の基本 1薬物の作用様式(薬理作用) 2細胞情報伝達系と受容体,
Nankodo, Jul. 2018.
2. Hiromichi Fujino and 村山 俊彦 :
(分担訳):第63章 アルツハイマー病,
ブレーン出版, 2010.
3. Hiromichi Fujino :
癌とプロスタグランジン,そしてその受容体,
国立大学法人千葉大学, 2010.

Academic Paper (Judged Full Paper):

1. Haruka Okabayashi, Miki Yasuda, Chinatsu Nii, Ryo Sugishita, Keijo Fukushima, Kouki Yuasa, Satoshi Kotoura and Hiromichi Fujino :
Phosphatidylcholine-Plasmalogen-Oleic Acid Reduces BACE1 Expression in Human SH-SY5Y Cells.,
Biological & pharmaceutical bulletin, Vol.47, No.1, 192-195, 2024.
(DOI: 10.1248/bpb.b23-00787,   PubMed: 38233149)
2. Masaki Imanishi, Takahisa Inoue, Keijo Fukushima, Ryosuke Yamashita, Ryo Nakayama, Masataka Nojima, Kosuke Kondo, Yoshiki Gomi, Honoka Tsunematsu, Kohei Goto, Licht Miyamoto, Masafumi Funamoto, Masaya Denda, Keisuke Ishizawa, Akira Otaka, Hiromichi Fujino, Yasumasa Ikeda and Koichiro Tsuchiya :
CA9 and PRELID2; hypoxia-responsive potential therapeutic targets for pancreatic ductal adenocarcinoma as per bioinformatics analyses.,
Journal of Pharmacological Sciences, Vol.153, No.4, 232-242, 2023.
(Tokushima University Institutional Repository: 119176,   DOI: 10.1016/j.jphs.2023.10.003,   PubMed: 37973221)
3. Ayaka Hamaguchi, Hayato Fukuda, Koichi Fujiwara, Tomofumi Harada, Keijo Fukushima, Satoshi Shuto and Hiromichi Fujino :
Individual resolvin E family members work distinctly and in a coordinated manner in the resolution of inflammation.,
Prostaglandins & Other Lipid Mediators, Vol.168, 106759, 2023.
(DOI: 10.1016/j.prostaglandins.2023.106759,   PubMed: 37327943,   Elsevier: Scopus)
4. Yuya Horinouchi, Yuka Murashima, Yuto Yamada, Shun Yoshioka, Keijo Fukushima, Takumi Kure, Naofumi Sasaki, Masaki Imanishi, Hiromichi Fujino, Koichiro Tsuchiya, Kazuaki Shinomiya and Yasumasa Ikeda :
Pemafibrate inhibited renal dysfunction and fibrosis in a mouse model of adenine-induced chronic kidney disease.,
Life Sciences, Vol.321, 121590, 2023.
(DOI: 10.1016/j.lfs.2023.121590,   PubMed: 36940907)
5. Takahiro Niimura, Yoshito Zamami, Koji Miyata, Takahisa Mikami, Mizuho Asada, Keijo Fukushima, Masaki Yoshino, Satoru Mitsuboshi, Naoto Okada, Hirofumi Hamano, Takumi Sakurada, Rie Matsuoka-Ando, Fuka Aizawa, Kenta Yagi, Mitsuhiro Goda, Masayuki Chuma, Toshihiro Koyama, Yuki Izawa-Ishizawa, Hiroaki Yanagawa, Hiromichi Fujino, Yoshihiro Yamanishi and Keisuke Ishizawa :
Characterization of Immune Checkpoint Inhibitor-Induced Myasthenia Gravis Using the US Food and Drug Administration Adverse Event Reporting System.,
Journal of Clinical Pharmacology, Vol.63, No.4, 473-479, 2022.
(DOI: 10.1002/jcph.2187,   PubMed: 36453166)
6. Natsuki Yamagiwa, Haruka Kobayashi, Haruka Okabayashi, Miki Yasuda, Keijo Fukushima, Jun Kawamura, Satoshi Kotoura and Hiromichi Fujino :
Phosphatidylcholine-Plasmalogen-Oleic Acid Has Protective Effects against Arachidonic Acid-Induced Cytotoxicity.,
Biological & Pharmaceutical Bulletin, Vol.45, No.5, 643-648, 2022.
(DOI: 10.1248/bpb.b22-00035,   PubMed: 35236811)
7. Yoshito Zamami, Takahiro Niimura, Takehiro Kawashiri, Mitsuhiro Goda, Yutaro Naito, Keijo Fukushima, Soichiro Ushio, Fuka Aizawa, Hirofumi Hamano, Naoto Okada, Kenta Yagi, Koji Miyata, Kenshi Takechi, Masayuki Chuma, Toshihiro Koyama, Daisuke Kobayashi, Takao Shimazoe, Hiromichi Fujino, Yuki Izawa-Ishizawa and Keisuke Ishizawa :
Identification of prophylactic drugs for oxaliplatin-induced peripheral neuropathy using big data.,
Biomedicine & Pharmacotherapy, Vol.148, 2022.
(Tokushima University Institutional Repository: 117414,   DOI: 10.1016/j.biopha.2022.112744,   PubMed: 35240525)
8. Kana Kitagawa, Ayaka Hamaguchi, Keijo Fukushima, Yuki Nakano, W John Regan, Masato Mashimo and Hiromichi Fujino :
Interleukin-4 may suppress expression of E-type prostanoid receptor4 in human colorectal cancer HCA-7 cells,
European Journal of Pharmacology, Vol.920, 2022.
(DOI: 10.1016/j.ejphar.2022.174863,   PubMed: 35240193)
9. Keijo Fukushima, Kanaho Senoo, Naoki Kurata, W John Regan and Hiromichi Fujino :
The Gαs-protein-mediated pathway may be steadily stimulated by prostanoid EP2 receptors, but not by EP4 receptors.,
FEBS Open Bio, Vol.12, No.4, 775-783, 2022.
(Tokushima University Institutional Repository: 117444,   DOI: 10.1002/2211-5463.13378,   PubMed: 35124898)
10. Keijo Fukushima and Hiromichi Fujino :
Identification and Characterization of Human Colorectal Cancer Cluster Predominantly Expressing EP3 Prostanoid Receptor Subtype.,
Biological & Pharmaceutical Bulletin, Vol.45, No.6, 698-702, 2022.
(DOI: 10.1248/bpb.b22-00104,   PubMed: 35650098)
11. Hirofumi Hamano, Yasumasa Ikeda, Mitsuhiro Goda, Keijo Fukushima, Seiji Kishi, Masayuki Chuma, Michiko Yamashita, Takahiro Niimura, Kenshi Takechi, Masaki Imanishi, Yoshito Zamami, Yuya Horinouchi, Izawa-Ishizawa Yuki, Licht Miyamoto, Ishizawa Keisuke, Hiromichi Fujino, Toshiaki Tamaki, Ken-ichi Aihara and Koichiro Tsuchiya :
Diphenhydramine may be a preventive medicine against cisplatin-induced kidney toxicity,
Kidney International, Vol.99, No.4, 885-889, 2021.
(Tokushima University Institutional Repository: 115399,   DOI: 10.1016/j.kint.2020.10.041,   PubMed: 33307103)
12. Iori Okura, Nanae Hasuoka, Kanaho Senoo, Akiko Suganami, Keijo Fukushima, W John Regan, Masato Mashimo, Toshihiko Murayama, Yutaka Tamura and Hiromichi Fujino :
The differential functional coupling of phosphodiesterase 4 to human DP and EP2 prostanoid receptors stimulated with PGD 2 or PGE 2,
Pharmacological Reports : PR, Vol.73, No.3, 946-953, 2021.
(DOI: 10.1007/s43440-021-00247-x,   PubMed: 33786738)
13. Motofumi Suzuki, Atsumi Urabe, Sayaka Sasaki, Ryo Tsugawa, Satoshi Nishio, Haruka Mukaiyama, Yoshiko Murata, Hiroshi Masuda, M. Sann Aung, Akane Mera, Masaki Takeuchi, Keijo Fukushima, Michika Kanaki, Kaori Kobayashi, Yudai Chiba, Binod Babu Shrestha, Hiromi Nakanishi, T. Watanabe, Atsushi Nakayama, Hiromichi Fujino, Takanori Kobayashi, Keiji Tanino, Naoko Nishizawa and Kosuke Namba :
Development of a mugineic acid family phytosiderophore analog as an iron fertilizer,
Nature Communications, Vol.12, No.1, 1558, 2021.
(Tokushima University Institutional Repository: 116178,   DOI: 10.1038/s41467-021-21837-6,   PubMed: 33692352)
14. Hiromichi Fujino :
Why PGD2 has different functions from PGE2,
BioEssays, Vol.43, No.2, e2000213, 2020.
(DOI: 10.1002/bies.202000213,   PubMed: 33165991)
15. Wakugawa Tomoharu, Nagamine Kenichi, Hiramatsu Miharu, Takeda Mayuko, Kawata Chika, Kashiwada Yoshiki, Shinohara Keiko, Sawada Eiji, Yabumoto Masami, Hiromichi Fujino, Yoshiaki Kitamura, Hiroyuki Fukui, Noriaki Takeda and Hiroyuki Mizuguchi :
Identification and characterization of the anti-allergic compound from lotus root.,
Traditional & Kampo Medicine, Vol.7, No.2, 85-95, 2020.
(DOI: 10.1002/tkm2.1249)
16. Suzu Endo, Akiko Suganami, Keijo Fukushima, Kanaho Senoo, Yumi Araki, W John Regan, Masato Mashimo, Yutaka Tamura and Hiromichi Fujino :
15-Keto-PGE 2 acts as a biased/partial agonist to terminate PGE 2-evoked signaling,
The Journal of Biological Chemistry, Vol.295, No.38, 13338-13352, 2020.
(Tokushima University Institutional Repository: 116544,   DOI: 10.1074/jbc.RA120.013988,   PubMed: 32727851)
17. Masaki Imanishi, Yusuke Yamakawa, Keijo Fukushima, Raiki Ikuto, Akiko Maegawa, Yuki Izawa-Ishizawa, Yuya Horinouchi, Masateru Kondo, Masatoshi Kishuku, Mitsuhiro Goda, Yoshito Zamami, Kenshi Takechi, Masayuki Chuma, Yasumasa Ikeda, Koichiro Tsuchiya, Hiromichi Fujino, Koichi Tsuneyama and Keisuke Ishizawa :
Fibroblast-specific ERK5 deficiency changes tumor vasculature and exacerbates tumor progression in a mouse model.,
Naunyn-Schmiedeberg's Archives of Pharmacology, Vol.393, No.7, 1239-1250, 2020.
(DOI: 10.1007/s00210-020-01859-5,   PubMed: 32307577)
18. Hirofumi Hamano, Takahiro Niimura, Yuya Horinouchi, Yoshito Zamami, Kenshi Takechi, Mitsuhiro Goda, Masaki Imanishi, Masayuki Chuma, Yuki Izawa-Ishizawa, Licht Miyamoto, Keijo Fukushima, Hiromichi Fujino, Koichiro Tsuchiya, Keisuke Ishizawa, Toshiaki Tamaki and Yasumasa Ikeda :
Proton pump inhibitors block iron absorption through direct regulation of hepcidin via the aryl hydrocarbon receptor-mediated pathway,
Toxicology Letters, Vol.318, 86-91, 2020.
(Tokushima University Institutional Repository: 113812,   DOI: 10.1016/j.toxlet.2019.10.016,   PubMed: 31669099)
19. Naoki Kurata, Natsumi Tokashiki, Keijo Fukushima, Takaya Misao, Nanae Hasuoka, Kana Kitagawa, Masato Mashimo, W John Regan, Toshihiko Murayama and Hiromichi Fujino :
Short chain fatty acid butyrate uptake reduces expressions of prostanoid EP4 receptors and their mediation of cyclooxygenase-2 induction in HCA-7 human colon cancer cells.,
European Journal of Pharmacology, Vol.853, 308-315, 2019.
(DOI: 10.1016/j.ejphar.2019.04.014,   PubMed: 30980797)
20. Hirofumi Hamano, Marin Mitsui, Yoshito Zamami, Kenshi Takechi, Takahiro Nimura, Naoto Okada, Keijo Fukushima, Masaki Imanishi, Masayuki Chuma, Yuya Horinouchi, Yuki Izawa-Ishizawa, Yasushi Kirino, Toshimi Nakamura, Kazuhiko Teraoka, Yasumasa Ikeda, Hiromichi Fujino, Hiroaki Yanagawa, Toshiaki Tamaki and Keisuke Ishizawa :
Irinotecan-induced neutropenia is reduced by oral alkalization drugs: analysis using retrospective chart reviews and the spontaneous reporting database.,
Supportive Care in Cancer, Vol.27, No.3, 849-856, 2019.
(DOI: 10.1007/s00520-018-4367-y,   PubMed: 30062585)
21. Masateru Kondo, Masaki Imanishi, Keijo Fukushima, Raiki Ikuto, Yoichi Murai, Yuya Horinouchi, Yuki Izawa-Ishizawa, Mitsuhiro Goda, Yoshito Zamami, Kenshi Takechi, Masayuki Chuma, Yasumasa Ikeda, Hiromichi Fujino, Koichiro Tsuchiya and Keisuke Ishizawa :
Xanthine Oxidase Inhibition by Febuxostat in Macrophages Suppresses Angiotensin II-induced Aortic Fibrosis.,
American Journal of Hypertension, Vol.32, No.3, 249-256, 2019.
(DOI: 10.1093/ajh/hpy157,   PubMed: 30351343)
22. Naofumi Seira, Kazuyuki Yamagata, Keijo Fukushima, Yumi Araki, Naoki Kurata, Naoki Yanagisawa, Masato Mashimo, Hiroyuki Nakamura, W John Regan, Toshihiko Murayama and Hiromichi Fujino :
Cellular density-dependent increases in HIF-1α compete with c-Myc to down-regulate human EP4 receptor promoter activity through Sp-1-binding region.,
Pharmacology Research & Perspectives, Vol.6, No.6, 2018.
(Tokushima University Institutional Repository: 115684,   DOI: 10.1002/prp2.441,   PubMed: 30455960)
23. Masaki Imanishi, Yuki Izawa-Ishizawa, T Sakurada, Y Kohara, Yuya Horinouchi, E Sairyo, Yoshito Zamami, Kenshi Takechi, Masayuki Chuma, Keijo Fukushima, Yasumasa Ikeda, Hiromichi Fujino, M Yoshizumi, Koichiro Tsuchiya, Toshiaki Tamaki and Keisuke Ishizawa :
Nitrosonifedipine, a Photodegradation Product of Nifedipine, Suppresses Pharmacologically Induced Aortic Aneurysm Formation.,
Pharmacology, Vol.102, No.5-6, 281-286, 2018.
(DOI: 10.1159/000492577,   PubMed: 30253416,   Elsevier: Scopus)
24. Yuya Horinouchi, Yasumasa Ikeda, Keijo Fukushima, Masaki Imanishi, Hirofumi Hamano, Yuki Izawa-Ishizawa, Yoshito Zamami, Kenshi Takechi, Licht Miyamoto, Hiromichi Fujino, Keisuke Ishizawa, Koichiro Tsuchiya and Toshiaki Tamaki :
Renoprotective effects of a factor Xa inhibitor: fusion of basic research and a database analysis.,
Scientific Reports, Vol.8, No.1, 2018.
(Tokushima University Institutional Repository: 112445,   DOI: 10.1038/s41598-018-29008-2,   PubMed: 30022146)
25. Aurpita Shaha, Hiroyuki Mizuguchi, Yoshiaki Kitamura, Hiromichi Fujino, Masami Yabumoto, Noriaki Takeda and Hiroyuki Fukui :
Receptor and Interleukin-9 Gene Expressions Responsible for the Pathogenesis of the Allergic Rhinitis.,
Biological & Pharmaceutical Bulletin, Vol.41, No.9, 1440-1447, 2018.
(DOI: 10.1248/bpb.b18-00325,   PubMed: 30175778)
26. Rezwanul Islam, Hiroyuki Mizuguchi, Aurpita Shaha, Kohei Nishida, Masami Yabumoto, Hisashi Ikeda, Hiromichi Fujino, Yoshiaki Kitamura, Hiroyuki Fukui and Noriaki Takeda :
Effect of wild grape on the signaling of histamine H1 receptor gene expression responsible for the pathogenesis of allergic rhinitis.,
The Journal of Medical Investigation : JMI, Vol.65, No.3.4, 242-250, 2018.
(Tokushima University Institutional Repository: 112246,   DOI: 10.2152/jmi.65.242,   PubMed: 30282868)
27. Takahiro Niimura, Yoshito Zamami, Toshihiro Koyama, Yuki Izawa-Ishizawa, Masashi Miyake, Tadashi Koga, Keisaku Harada, Ayako Ohshima, Toru Imai, Yutaka Kondo, Masaki Imanishi, Kenshi Takechi, Keijo Fukushima, Yuya Horinouchi, Yasumasa Ikeda, Hiromichi Fujino, Koichiro Tsuchiya, Toshiaki Tamaki, Shiro Hinotsu, R Mitsunobu Kano and Keisuke Ishizawa :
Hydrocortisone administration was associated with improved survival in Japanese patients with cardiac arrest.,
Scientific Reports, Vol.7, No.1, 2017.
(Tokushima University Institutional Repository: 112397,   DOI: 10.1038/s41598-017-17686-3,   PubMed: 29263333)
28. Araki Yumi, Suganami Akiko, Endo Suzu, Masuda Yuta, Keijo Fukushima, Regan W. John, Murayama Toshihiko, Tamura Yutaka and Hiromichi Fujino :
PGE1 and E3 show lower efficacies than E2 to -catenin-mediated activity as biased ligands of EP4 prostanoid receptors.,
FEBS Letters, Vol.591, No.22, 3771-3780, 2017.
(DOI: 10.1002/1873-3468.12878,   PubMed: 28986997)
29. Akiko Suganami, Hiromichi Fujino, Iori Okura, Naoki Yanagisawa, Hajime Sugiyama, W John Regan, Yutaka Tamura and Toshihiko Murayama :
Human DP and EP2 prostanoid receptors take on distinct forms depending on the diverse binding of different ligands.,
The FEBS Journal, Vol.283, No.21, 3931-3940, 2016.
(DOI: 10.1111/febs.13899,   PubMed: 27636113)
30. Hiromichi Fujino, Naofumi Seira, Naoki Kurata, Yumi Araki, Hiroyuki Nakamura, W John Regan and Toshihiko Murayama :
Prostaglandin E2-stimulated prostanoid EP4 receptors induce prolonged de novo prostaglandin E2 synthesis through biphasic phosphorylation of extracellular signal-regulated kinases mediated by activation of protein kinase A in HCA-7 human colon cancer cells.,
European Journal of Pharmacology, Vol.768, 149-159, 2015.
(DOI: 10.1016/j.ejphar.2015.10.044,   PubMed: 26518053)
31. Satoshi Yamane, Ryouya Nomura, Madoka Yanagihara, Hiroyuki Nakamura, Hiromichi Fujino, Kenjiro Matsumoto, Syunji Horie and Toshihiko Murayama :
L-Cysteine/D,L-homocysteine-regulated ileum motility via system L and B°(,+) transporter: Modification by inhibitors of hydrogen sulfide synthesis and dietary treatments.,
European Journal of Pharmacology, Vol.764, 471-479, 2015.
(DOI: 10.1016/j.ejphar.2015.07.042,   PubMed: 26201052)
32. Sho Otake, Kenji Yoshida, Naofumi Seira, M Christopher Sanchez, W John Regan, Hiromichi Fujino and Toshihiko Murayama :
Cellular density-dependent down-regulation of EP4 prostanoid receptors via the up-regulation of hypoxia-inducible factor-1 in HCA-7 human colon cancer cells.,
Pharmacology Research & Perspectives, Vol.3, No.1, e00083, 2014.
(DOI: 10.1002/prp2.83,   PubMed: 25692008)
33. Satoshi Yamane, Toshio Kanno, Hiroyuki Nakamura, Hiromichi Fujino and Toshihiko Murayama :
Hydrogen sulfide-mediated regulation of contractility in the mouse ileum with electrical stimulation: roles of L-cysteine, cystathionine -synthase, and K+ channels.,
European Journal of Pharmacology, Vol.740, 112-120, 2014.
(DOI: 10.1016/j.ejphar.2014.06.054,   PubMed: 25008073)
34. T Hosoya, K Matsumoto, K Tashima, H Nakamura, Hiromichi Fujino, T Murayama and S Horie :
TRPM8 has a key role in experimental colitis-induced visceral hyperalgesia in mice.,
Neurogastroenterology and Motility, Vol.26, No.8, 1112-1121, 2014.
(DOI: 10.1111/nmo.12368,   PubMed: 24832648)
35. Satomi Oyama, Hiromichi Fujino, Risa Yamazaki, Iori Okura, W John Regan, Atsuko Awata, Takayoshi Arai and Toshihiko Murayama :
A novel indole compound, AWT-489, inhibits prostaglandin D2-induced CD55 expression by acting on DP prostanoid receptors as an antagonist in LS174T human colon cancer cells.,
Archives of Biochemistry and Biophysics, Vol.541, 21-29, 2013.
(DOI: 10.1016/j.abb.2013.10.023,   PubMed: 24239863)
36. Ryouya Nomura, Madoka Yanagihara, Hiromi Sato, Kenjiro Matsumoto, Kimihito Tashima, Shunji Horie, Shuonan Chen, Hiromichi Fujino, Kouichi Ueno and Toshihiko Murayama :
Bee venom phospholipase A2-induced phasic contractions in mouse rectum: independent roles of eicosanoid and gap junction proteins and their loss in experimental colitis.,
European Journal of Pharmacology, Vol.718, No.1-3, 314-322, 2013.
(DOI: 10.1016/j.ejphar.2013.08.015,   PubMed: 24012929)
37. Kenji Yoshida, Hiromichi Fujino, Sho Otake, Naofumi Seira, W John Regan and Toshihiko Murayama :
Induction of cyclooxygenase-2 expression by prostaglandin E2 stimulation of the prostanoid EP4 receptor via coupling to Gi and transactivation of the epidermal growth factor receptor in HCA-7 human colon cancer cells.,
European Journal of Pharmacology, Vol.718, No.1-3, 408-417, 2013.
(DOI: 10.1016/j.ejphar.2013.08.002,   PubMed: 23973650)
38. Tatsuo Kawashima, Risa Yamazaki, Yasuo Matsuzawa, Erika Yamaura, Mamoru Takabatake, Sho Otake, Yuta Ikawa, Hiroyuki Nakamura, Hiromichi Fujino and Toshihiko Murayama :
Contrary effects of sphingosine-1-phosphate on expression of -smooth muscle actin in transforming growth factor 1-stimulated lung fibroblasts.,
European Journal of Pharmacology, Vol.696, No.1-3, 120-129, 2012.
(DOI: 10.1016/j.ejphar.2012.09.038,   PubMed: 23041148)
39. Hiroyuki Nakamura, Kana Yasufuku, Tomohiko Makiyama, Ikiru Matsumoto, Hiromichi Fujino and Toshihiko Murayama :
Arachidonic acid metabolism via cytosolic phospholipase A2 induces cytotoxicity in niemann-pick disease type C cells.,
Journal of Cellular Physiology, Vol.227, No.7, 2847-2855, 2012.
(DOI: 10.1002/jcp.23025,   PubMed: 21928312)
40. Yuta Ikawa, Hiromichi Fujino, Sho Otake and Toshihiko Murayama :
Indomethacin antagonizes EP(2) prostanoid receptor activation in LS174T human colon cancer cells.,
European Journal of Pharmacology, Vol.680, No.1-3, 16-21, 2012.
(DOI: 10.1016/j.ejphar.2012.01.033,   PubMed: 22329897)
41. Koichi Kawada, Masayuki Kaneko, Yasuyuki Nomura, Seisuke Mimori, Hiroshi Hamana, Kiyokazu Ogita, Toshihiko Murayama, Hiromichi Fujino and Yasunobu Okuma :
Expression of the ubiquitin ligase HRD1 in neural stem/progenitor cells of the adult mouse brain.,
Journal of Pharmacological Sciences, Vol.117, No.3, 208-212, 2011.
(DOI: 10.1254/jphs.11120SC,   PubMed: 22027098)
42. Yuri Hamada, Erina Kato, Hiroyuki Nakamura, Hiromichi Fujino, Kenjiro Matsumoto, Kimihito Tashima, Shunji Horie and Toshihiko Murayama :
Decrease of guanylyl cyclase 1 subunit and nitric oxide (NO)-induced relaxation in mouse rectum with colitis and its reproduction on long-term NO treatment.,
Naunyn-Schmiedeberg's Archives of Pharmacology, Vol.385, No.1, 81-94, 2011.
(DOI: 10.1007/s00210-011-0681-3,   PubMed: 21947227)
43. Erina Kato, Satoshi Yamane, Ryoya Nomura, Kenjiro Matsumoto, Kimihito Tashima, Shunji Horie, Takeshi Saito, Hiromichi Fujino and Toshihiko Murayama :
Dysfunction of neurogenic VIP-mediated relaxation in mouse distal colon with dextran sulfate sodium-induced colitis.,
Pharmacological Research, Vol.65, No.2, 204-212, 2011.
(DOI: 10.1016/j.phrs.2011.09.004,   PubMed: 21939768)
44. Tomoko Kato, Hiromichi Fujino, Satomi Oyama, Tatsuo Kawashima and Toshihiko Murayama :
Indomethacin induces cellular morphological change and migration via epithelial-mesenchymal transition in A549 human lung cancer cells: a novel cyclooxygenase-inhibition-independent effect.,
Biochemical Pharmacology, Vol.82, No.11, 1781-1791, 2011.
(DOI: 10.1016/j.bcp.2011.07.096,   PubMed: 21840302)
45. Yasuo Matsuzawa, Tatsuo Kawashima, Risa Yamazaki, Erika Yamaura, Tomohiko Makiyama, Hiromichi Fujino and Toshihiko Murayama :
Inhibitory effects of clinical reagents having anti-oxidative activity on transforming growth factor-1-induced expression of -smooth muscle actin in human fetal lung fibroblasts.,
The Journal of Toxicological Sciences, Vol.36, No.6, 733-740, 2011.
(PubMed: 22129737)
46. Hiromichi Fujino, Kaori Toyomura, Xiao-bo Chen, W John Regan and Toshihiko Murayama :
Prostaglandin E2 regulates cellular migration via induction of vascular endothelial growth factor receptor-1 in HCA-7 human colon cancer cells.,
Biochemical Pharmacology, Vol.81, No.3, 379-387, 2010.
(DOI: 10.1016/j.bcp.2010.11.001,   PubMed: 21070749)
47. Takashi Orido, Hiromichi Fujino, Tatsuo Kawashima and Toshihiko Murayama :
Decrease in uptake of arachidonic acid by indomethacin in LS174T human colon cancer cells; a novel cyclooxygenase-2-inhibition-independent effect.,
Archives of Biochemistry and Biophysics, Vol.494, No.1, 78-85, 2009.
(DOI: 10.1016/j.abb.2009.11.025,   PubMed: 19944063)
48. Yasuo Matsuzawa, Yoshiaki Kiuchi, Kaori Toyomura, Ikiru Matsumoto, Hiroyuki Nakamura, Hiromichi Fujino, Toshihiko Murayama and Tatsuo Kawashima :
Activation of cytosolic phospholipase A2alpha by epidermal growth factor (EGF) and phorbol ester in HeLa cells: different effects of inhibitors for EGF receptor, protein kinase C, Src, and C-Raf.,
Journal of Pharmacological Sciences, Vol.111, No.2, 182-192, 2009.
(DOI: 10.1254/jphs.09201FP,   PubMed: 19783865)
49. Yuri Hamada, Ikuo Murakami, Erina Kato, Satoshi Yamane, Hiromichi Fujino, Kenjiro Matsumoto, Kimihito Tashima, Shunji Horie and Toshihiko Murayama :
Neurogenic contraction of mouse rectum via the cyclooxygenase pathway: Changes of PGE2-induced contraction with dextran sulfate sodium-induced colitis.,
Pharmacological Research, Vol.61, No.1, 48-57, 2009.
(DOI: 10.1016/j.phrs.2009.09.001,   PubMed: 19744562)
50. Takeshi Kurosawa, Hiroyuki Nakamura, Erika Yamaura, Hiromichi Fujino, Yasuo Matsuzawa, Tatsuo Kawashima and Toshihiko Murayama :
Cytotoxicity induced by inhibition of thioredoxin reductases via multiple signaling pathways: role of cytosolic phospholipase A(2)alpha-dependent and -independent release of arachidonic acid.,
Journal of Cellular Physiology, Vol.219, No.3, 606-616, 2009.
(DOI: 10.1002/jcp.21703,   PubMed: 19170071)
51. Masaya Shimizu, Yuki Muramatsu, Eiko Tada, Takeshi Kurosawa, Erika Yamaura, Hiroyuki Nakamura, Hiromichi Fujino, Yuuya Houjyo, Yuri Miyasaka, Yuuki Koide, Atsushi Nishida and Toshihiko Murayama :
Effects of synthetic sphingosine-1-phosphate analogs on cytosolic phospholipase A2alpha-independent release of arachidonic acid and cell toxicity in L929 fibrosarcoma cells: the structure-activity relationship.,
Journal of Pharmacological Sciences, Vol.109, No.3, 431-443, 2009.
(DOI: 10.1254/jphs.08284FP,   PubMed: 19276615)
52. Ikuo Murakami, Yuri Hamada, Satoshi Yamane, Hiromichi Fujino, Shunji Horie and Toshihiko Murayama :
Nicotine-induced neurogenic relaxation in the mouse colon: changes with dextran sodium sulfate-induced colitis.,
Journal of Pharmacological Sciences, Vol.109, No.1, 128-138, 2009.
(DOI: 10.1254/jphs.08241FP,   PubMed: 19129681)
53. Masaya Shimizu, Eiko Tada, Tomohiko Makiyama, Kana Yasufuku, Yuta Moriyama, Hiromichi Fujino, Hiroyuki Nakamura and Toshihiko Murayama :
Effects of ceramide, ceramidase inhibition and expression of ceramide kinase on cytosolic phospholipase A2alpha; additional role of ceramide-1-phosphate in phosphorylation and Ca2+ signaling.,
Cellular Signalling, Vol.21, No.3, 440-447, 2008.
(DOI: 10.1016/j.cellsig.2008.11.014,   PubMed: 19101626)
54. Maiko Nabemoto, Masato Mashimo, Akiyoshi Someya, Hiroyuki Nakamura, Tetsuya Hirabayashi, Hiromichi Fujino, Masayuki Kaneko, Yasunobu Okuma, Takeshi Saito, Naoto Yamaguchi and Toshihiko Murayama :
Release of arachidonic acid by 2-arachidonoyl glycerol and HU210 in PC12 cells; roles of Src, phospholipase C and cytosolic phospholipase A(2)alpha.,
European Journal of Pharmacology, Vol.590, No.1-3, 1-11, 2008.
(DOI: 10.1016/j.ejphar.2008.04.064,   PubMed: 18539271)
55. Wei Xu, Chih-Ling Chou, Haipeng Sun, Hiromichi Fujino, M Qin Chen and W John Regan :
FP prostanoid receptor-mediated induction of the expression of early growth response factor-1 by activation of a Ras/Raf/mitogen-activated protein kinase signaling cascade.,
Molecular Pharmacology, Vol.73, No.1, 111-118, 2007.
(DOI: 10.1124/mol.107.038778,   PubMed: 17911534)
56. Tomoko Taniguchi, Masaya Shimizu, Hiroyuki Nakamura, Tetsuya Hirabayashi, Hiromichi Fujino, Takeshi Saito and Toshihiko Murayama :
Vanadate-induced activation of cytosolic phospholipase A2alpha in L929 cells: Roles of tyrosine kinase, protein kinase C, and extracellular signal-regulated kinase.,
Biochemical Pharmacology, Vol.73, No.6, 854-862, 2006.
(DOI: 10.1016/j.bcp.2006.11.026,   PubMed: 17188653)
57. Tomoko Taniguchi, Masaya Shimizu, Hiroyuki Nakamura, Tetsuya Hirabayashi, Hiromichi Fujino and Toshihiko Murayama :
Hydrogen peroxide-induced arachidonic acid release in L929 cells; roles of Src, protein kinase C and cytosolic phospholipase A2alpha.,
European Journal of Pharmacology, Vol.546, No.1-3, 1-10, 2006.
(DOI: 10.1016/j.ejphar.2006.06.071,   PubMed: 16914136)
58. Nobuteru Akiyama, Maiko Nabemoto, Yoshio Hatori, Hiroyuki Nakamura, Tetsuya Hirabayashi, Hiromichi Fujino, Takeshi Saito and Toshihiko Murayama :
Up-regulation of cytosolic phospholipase A2alpha expression by N,N-diethyldithiocarbamate in PC12 cells; involvement of reactive oxygen species and nitric oxide.,
Toxicology and Applied Pharmacology, Vol.215, No.2, 218-227, 2006.
(DOI: 10.1016/j.taap.2006.02.013,   PubMed: 16603213)
59. Hiromichi Fujino and W John Regan :
EP(4) prostanoid receptor coupling to a pertussis toxin-sensitive inhibitory G protein.,
Molecular Pharmacology, Vol.69, No.1, 5-10, 2005.
(DOI: 10.1124/mol.105.017749,   PubMed: 16204467)
60. Hiromichi Fujino, Sambhitab Salvi and W John Regan :
Differential regulation of phosphorylation of the cAMP response element-binding protein after activation of EP2 and EP4 prostanoid receptors by prostaglandin E2.,
Molecular Pharmacology, Vol.68, No.1, 251-259, 2005.
(DOI: 10.1124/mol.105.011833,   PubMed: 15855407)
61. Hiromichi Fujino, A George Vielhauer and W John Regan :
Prostaglandin E2 selectively antagonizes prostaglandin F2alpha-stimulated T-cell factor/beta-catenin signaling pathway by the FPB prostanoid receptor.,
The Journal of Biological Chemistry, Vol.279, No.42, 43386-43391, 2004.
(DOI: 10.1074/jbc.M408276200,   PubMed: 15280380)
62. A George Vielhauer, Hiromichi Fujino and W John Regan :
Cloning and localization of hFP(S): a six-transmembrane mRNA splice variant of the human FP prostanoid receptor.,
Archives of Biochemistry and Biophysics, Vol.421, No.2, 175-185, 2004.
(DOI: 10.1016/j.abb.2003.10.021,   PubMed: 14984197)
63. Hiromichi Fujino, Wei Xu and W John Regan :
Prostaglandin E2 induced functional expression of early growth response factor-1 by EP4, but not EP2, prostanoid receptors via the phosphatidylinositol 3-kinase and extracellular signal-regulated kinases.,
The Journal of Biological Chemistry, Vol.278, No.14, 12151-12156, 2003.
(DOI: 10.1074/jbc.M212665200,   PubMed: 12566441)
64. Hiromichi Fujino, Dinesh Srinivasan and W John Regan :
Cellular conditioning and activation of beta-catenin signaling by the FPB prostanoid receptor.,
The Journal of Biological Chemistry, Vol.277, No.50, 48786-48795, 2002.
(DOI: 10.1074/jbc.M209393200,   PubMed: 12368277)
65. Dinesh Srinivasan, Hiromichi Fujino and W John Regan :
Differential internalization of the prostaglandin f(2alpha) receptor isoforms: role of protein kinase C and clathrin.,
The Journal of Pharmacology and Experimental Therapeutics, Vol.302, No.1, 219-224, 2002.
(PubMed: 12065720)
66. L Todd Anthony, Hiromichi Fujino, L Kristen Pierce, J Andrea Yool and W John Regan :
Differential regulation of Ca(2+)-dependent Cl- currents by FP prostanoid receptor isoforms in Xenopus oocytes.,
Biochemical Pharmacology, Vol.63, No.10, 1797-1806, 2002.
(DOI: 10.1016/S0006-2952(02)00953-X,   PubMed: 12034364)
67. Hiromichi Fujino, A Kimberly West and W John Regan :
Phosphorylation of glycogen synthase kinase-3 and stimulation of T-cell factor signaling following activation of EP2 and EP4 prostanoid receptors by prostaglandin E2.,
The Journal of Biological Chemistry, Vol.277, No.4, 2614-2619, 2001.
(DOI: 10.1074/jbc.M109440200,   PubMed: 11706038)
68. Hiromichi Fujino, T Uehara, T Murayama, Y Okuma, H Ariga and Y Nomura :
Extracellular signal regulated protein kinase and c-jun N-terminal kinase are involved in ml muscarinic receptor-enhanced interleukin-2 production pathway in Jurkat cells.,
Biological & Pharmaceutical Bulletin, Vol.23, No.10, 1198-1205, 2000.
(PubMed: 11041251)
69. Hiromichi Fujino, L K Pierce, D Srinivasan, E C Protzman, H A Krauss, F D Woodward and W J Regan :
Delayed reversal of shape change in cells expressing FP(B) prostanoid receptors. Possible role of receptor resensitization.,
The Journal of Biological Chemistry, Vol.275, No.38, 29907-29914, 2000.
(DOI: 10.1074/jbc.M003467200,   PubMed: 10893233)
70. Hiromichi Fujino, D Srinivasan, L K Pierce and W J Regan :
Differential regulation of prostaglandin F(2alpha) receptor isoforms by protein kinase C.,
Molecular Pharmacology, Vol.57, No.2, 353-358, 2000.
(PubMed: 10648645)
71. L K Pierce, Hiromichi Fujino, D Srinivasan and W J Regan :
Activation of FP prostanoid receptor isoforms leads to Rho-mediated changes in cell morphology and in the cell cytoskeleton.,
The Journal of Biological Chemistry, Vol.274, No.50, 35944-35949, 1999.
(PubMed: 10585482)
72. C Hayashi, Hiromichi Fujino, M Ogata, Y Sato, M S Iguchi-Ariga and H Ariga :
Determination of the functional domain of a mouse autonomous replicating sequence.,
Biological & Pharmaceutical Bulletin, Vol.20, No.6, 690-693, 1997.
(PubMed: 9212992)
73. Hiromichi Fujino, Y Kitamura, T Yada, T Uehara and Y Nomura :
Stimulatory roles of muscarinic acetylcholine receptors on T cell antigen receptor/CD3 complex-mediated interleukin-2 production in human peripheral blood lymphocytes.,
Molecular Pharmacology, Vol.51, No.6, 1007-1014, 1997.
(PubMed: 9187267)

Academic Paper (Unrefereed Paper):

1. Hiromichi Fujino :
Recent Advances of GPCR Studies: An Old-Fashioned Perspective?,
Biological & Pharmaceutical Bulletin, Vol.45, No.6, 668, 2022.
(DOI: 10.1248/bpb.b22-ctf4506)

Academic Letter:

1. Masato Mashimo, Asuka Shimizu, Aimi Mori, Ayaka Hamaguchi, Keijo Fukushima, Naofumi Seira, Takeshi Fujii and Hiromichi Fujino :
PARP14 regulates EP4 receptor expression in human colon cancer HCA-7 cells.,
Biochemical and Biophysical Research Communications, Vol.623, 133-139, 2022.
(DOI: 10.1016/j.bbrc.2022.07.055,   PubMed: 35914351)
2. Seira Naofumi, Yanagisawa Naoki, Suganami Akiko, Takuya Honda, Wasai Makiko, Regan W John, Keijo Fukushima, Yamaguchi Naoto, Tamura Yutaka, Arai Takayoshi, Murayama Toshihiko and Hiromichi Fujino :
Anti-cancer effects of MW-03, a novel indole compound, by inducing 15-hydroxyprostaglandin dehydrogenase and cellular growth inhibition in the LS174T human colon cancer cell line,
Biological & Pharmaceutical Bulletin, Vol.40, No.10, 1806-1812, 2017.
(DOI: 10.1248/bpb.b17-00458,   PubMed: 28966256,   Elsevier: Scopus)
3. Jun Tanimoto, Hiromichi Fujino, Hiroki Takahashi and Toshihiko Murayama :
Human EP2 prostanoid receptors exhibit more constraints to mutations than human DP prostanoid receptors.,
FEBS Letters, Vol.589, No.6, 766-772, 2015.
(DOI: 10.1016/j.febslet.2015.02.006,   PubMed: 25681680)
4. Takashi Orido, Hiromichi Fujino, Yuta Hasegawa, Kaori Toyomura, Tatsuo Kawashima and Toshihiko Murayama :
Indomethacin decreases arachidonic acid uptake in HCA-7 human colon cancer cells.,
Journal of Pharmacological Sciences, Vol.108, No.3, 389-392, 2008.
(DOI: 10.1254/jphs.08167SC,   PubMed: 18987430)
5. Tomoko Taniguchi, Hiromichi Fujino, D Davelene Israel, W John Regan and Toshihiko Murayama :
Human EP3(I) prostanoid receptor induces VEGF and VEGF receptor-1 mRNA expression.,
Biochemical and Biophysical Research Communications, Vol.377, No.4, 1173-1178, 2008.
(DOI: 10.1016/j.bbrc.2008.10.140,   PubMed: 18996083)
6. Hiromichi Fujino, Xiao-bo Chen, W John Regan and Toshihiko Murayama :
Indomethacin decreases EP2 prostanoid receptor expression in colon cancer cells.,
Biochemical and Biophysical Research Communications, Vol.359, No.3, 568-573, 2007.
(DOI: 10.1016/j.bbrc.2007.05.145,   PubMed: 17555711)
7. Hiromichi Fujino and W John Regan :
Prostaglandin F2alpha amplifies tumor necrosis factor-alpha promoter activity by the FPB prostanoid receptor.,
Biochemical and Biophysical Research Communications, Vol.317, No.4, 1114-1120, 2004.
(DOI: 10.1016/j.bbrc.2004.03.167,   PubMed: 15094384)
8. Hiromichi Fujino and W John Regan :
Prostaglandin F stimulation of cyclooxygenase-2 promoter activity by the FPB prostanoid receptor.,
European Journal of Pharmacology, Vol.465, No.1-2, 39-41, 2003.
(DOI: 10.1016/s0014-2999(03)01485-7,   PubMed: 12650831)
9. Hiromichi Fujino and W J Regan :
FP prostanoid receptor activation of a T-cell factor/beta -catenin signaling pathway.,
The Journal of Biological Chemistry, Vol.276, No.16, 12489-12492, 2001.
(DOI: 10.1074/jbc.C100039200,   PubMed: 11278257)

Review, Commentary:

1. Hiromichi Fujino :
The Biased Activities of Prostanoids and Their Receptors: Review and Beyond.,
Biological & Pharmaceutical Bulletin, Vol.45, No.6, 684-690, 2022.
(DOI: 10.1248/bpb.b21-01052,   PubMed: 35650096)
2. Hiromichi Fujino :
Foreword.,
Biological & Pharmaceutical Bulletin, Vol.45, No.6, 2022.
(DOI: 10.1248/bpb.b22-ctf4506,   PubMed: 35650093)
3. Hiromichi Fujino :
旬の研究紹介「バイアス・リガンドが受容体を翻弄する?」,
医歯薬学研究部だより, Vol.8, 5, Oct. 2018.
4. Hiromichi Fujino :
研究室へようこそ「治癒力のメカニズムを探る生命探求の世界へ」,
とくTalk, Vol.169, 7-8, Oct. 2017.
5. Hiromichi Fujino :
The Roles of EP4 Prostanoid Receptors in Cancer Malignancy Signaling.,
Biological & Pharmaceutical Bulletin, Vol.39, No.2, 149-155, 2016.
(DOI: 10.1248/bpb.b15-00840,   PubMed: 26830476)
6. Hiromichi Fujino and Toshihiko Murayama :
[Novel anti-cancer effects of indomethacin: exploring the cyclooxygenase-inhibition-independent effects].,
Folia Pharmacologica Japonica, Vol.137, No.4, 177-181, Apr. 2011.
(PubMed: 21478637)
7. Hiromichi Fujino, Toshihiko Murayama and W John Regan :
Assessment of constitutive activity in E-type prostanoid receptors.,
Methods in Enzymology, Vol.484, 95-107, 2010.
(DOI: 10.1016/B978-0-12-381298-8.00005-8,   PubMed: 21036228)
8. Hiromichi Fujino and W John Regan :
Prostanoid receptors and phosphatidylinositol 3-kinase: a pathway to cancer?,
Trends in Pharmacological Sciences, Vol.24, No.7, 335-340, Jul. 2003.
(DOI: 10.1016/S0165-6147(03)00162-7,   PubMed: 12871665)

Proceeding of International Conference:

1. Niimura Takahiro, Yoshito Zamami, Yuki Izawa-Ishizawa, Mitsuhiro Goda, Kenshi Takechi, Masayuki Chuma, Keijo Fukushima, Yuya Horinouchi, Hiromichi Fujino, Koichiro Tsuchiya and Keisuke Ishizawa :
Nicorandil improve prognosis of cardiac arrest patient: A large-scale medical information analysis,
FIP2019, Abu Dhabi, Sep. 2019.
2. Hiromichi Fujino :
The functions of receptors for prostanoids are tossed up and down by endogenous cognate and/or non-cognate ligands,
The 4th symposium of integrated research institute for drug development, College of Pharmacy, Dongguk University, Oct. 2018.
3. Yuya Horinouchi, Yasumasa Ikeda, Keijo Fukushima, Masaki Imanishi, Yuki Izawa-Ishizawa, Yoshito Zamami, Hiromichi Fujino, Keisuke Ishizawa, Koichiro Tsuchiya and Toshiaki Tamaki :
Utilizing Real-World Big Data in the Search for New Renoprotective Drugs,
Joint Hypertension 2018 Scientific Sessions, Sep. 2018.
4. Seira Naofumi, Yamagata Kazuyuki, Keijo Fukushima, Araki Yumi, Kurata Naoki, Yanagisawa Naoki, Mashimo Masato, Nakamura Hiroyuki, Regan W. John, Murayama Toshihiko and Hiromichi Fujino :
Hypoxia inducible factor-1alpha regulates human EP4 receptor expression by binding to specificity protein-1,
The 3rd Chiba University-Mahidol University Joint Symposium on Pharmaceutical Sciences, Aug. 2018.
5. Nishida Kohei, Mizuguchi Hiroyuki, Nakano Tomohiro, Kitamura Noriko, Kaminuma Osamu, Uchida Masayuki, Kamimura Seiichiro, Kitamura Yoshiaki, Hiromichi Fujino, Takeda Noriaki and Fukui Hiroyuki :
Anti-allergic compound pyrogallol extracted from Awa bancha suppresses calcineurin (CN)/nuclear factor of activated T-cells (NFAT) signaling,
World Histamine Symposium 2018, Jul. 2018.
6. Hiramatsu Miharu, Mizuguchi Hiroyuki, Wakugawa Tomoharu, Nagamine Kenichi, Tanabe Hideya, Shinohara Keiko, Sawada Eiji, Hiromichi Fujino, Kitamura Yoshiaki, Takeda Noriaki and Fukui Hiroyuki :
Isolation of anti-allergic compound from lotus roots,
World Histamine Symposium 2018, Jul. 2018.
7. Islam Rezwanul, Shaha Aurpita, Okamoto Kentaro, Wakugawa Tomoharu, Nishida Kohei, Yabumoto Masami, Ikeda Hisashi, Hiromichi Fujino, Fukui Hiroyuki, Takeda Noriaki and Mizuguchi Hiroyuki :
Nasal symptoms in allergic model rats markedly alleviated by the combination therapy with wild grapes and Awa-tea,
World Histamine Symposium 2018, Jul. 2018.
8. Shaha Aurpita, Mizuguchi Hiroyuki, Islam Rezwanul, Wakugawa Tomoharu, Hiromichi Fujino, Yabumoto Masami, Takeda Noriaki and Fukui Hiroyuki :
Effect of Royal jerry and Brazilian green propolis on the signaling for histamine H1 receptor and interleukin-9 gene expressions responsible for the pathogenesis of the allergic rhinitis,
World Histamine Symposium 2018, Jul. 2018.
9. Konishi Yuki, Mizuguchi Hiroyuki, Kitamura Yoshiaki, Hiromichi Fujino, Takeda Noriaki and Fukui Hiroyuki :
Effect of Sho-seiryu-to on histamine H1 receptor and interleukin-33 gene expression,
World Histamine Symposium 2018, Jul. 2018.
10. Kyuta Ayumi, Mizuguchi Hiroyuki, Kawai Makiko, Hiromichi Fujino, Kitamura Yoshiaki, Takeda Noriaki and Fukui Hiroyuki :
Effect of anti-allergic compound (-)-maackiain isolated from kujin on steroid signaling,
World Histamine Symposium 2018, Jul. 2018.
11. Sanada Nanae, Mizuguchi Hiroyuki, Kamimura Seiichiro, Fujii Tatuya, Yamada Takuya, Kitamura Yoshiaki, Hiromichi Fujino, Takeda Noriaki and Fukui Hiroyuki :
Effect of narrow-band UVB on up-regulation of histamine H1 receptor gene expression in HeLa cells,
World Histamine Symposium 2018, Jul. 2018.
12. Yuya Horinouchi, Yasumasa Ikeda, Keijo Fukushima, Masaki Imanishi, Yuki Izawa-Ishizawa, Yoshito Zamami, Hiromichi Fujino, Keisuke Ishizawa, Koichiro Tsuchiya and Toshiaki Tamaki :
Renoprotective effects of edoxaban, a factor Xa inhibitor,
18th World Congress of Basic and Clinical Pharmacology, Jul. 2018.
13. Yoshito Zamami, Yuki Izawa-Ishizawa, Kenshi Takechi, Masaki Imanishi, Keijo Fukushima, Yuya Horinouchi, Yasumasa Ikeda, Hiromichi Fujino, Toshiaki Tamaki and Keisuke Ishizawa :
Search for drugs that attenuate the anti tumor effect of bevacizumab using adverse event database,
18th World Congress of Basic and Clinical Pharmacology, Jul. 2018.
14. Wakugawa Tomoharu, Mizuguchi Hiroyuki, Hiramatsu Miharu, Nagamine Ken-ichi, Tanabe Hideya, Shinohara Keiko, Sawada Eiji, Hiromichi Fujino, Fukui Hiroyuki and Takeda Noriaki :
Isolation of anti-allergic compound from Lotus Root,
18th World Congress of Basic and Clinical Pharmacology, Jul. 2018.
15. Hiromichi Fujino, Araki Yumi, Suganami Akiko, Endo Suzu, Takano Harumi, Masuda Yuta, Keijo Fukushima, Regan W. John, Murayama Toshihiko and Tamura Yutaka :
PGE1 and E3 show lower efficacies than E2 to beta-catenin-mediated activity as biased ligands of EP4 prostanoid receptors,
18th World Congress of Basic and Clinical Pharmacology, Jul. 2018.
16. Islam Rezwanul, Shaha Aurpita, Okamoto Kentaro, Wakugawa Tomoharu, Hiramatsu Miharu, Ikeda Hisashi, Hiromichi Fujino, Fukui Hiroyuki and Mizuguchi Hiroyuki :
Wild grapes in a combination with Awa tea markedly alleviated nasal symptoms in toluene-2,4-diisocyanate-sensitized allergy model rats.,
The 18th International Congress of International Society for Ethnopharmacology& the 5th International Congress of the Society for Ethnopharmacology, Jan. 2018.
17. Seira Naofumi, Hiromichi Fujino, Otake Sho, Regan W. John, Takahashi Hiroki and Murayama Toshihiko :
EP4 prostanoid receptor expression by HIF-1a in human colon cancer HCA-7 cell line.,
2nd World Congress of Cancer Research & Therapy, Oct. 2017.
18. Masaki Imanishi, Kyohei Tanaka, Raiki Ikutoh, Yoshito Zamami, Kenshi Takechi, Yuya Horinouchi, Yuki Izawa-Ishizawa, Yasumasa Ikeda, Hiromichi Fujino, Koichiro Tsuchiya, Toshiaki Tamaki and Keisuke Ishizawa :
THE EFFECTS OF FEBUXOSTAT ON ANGIOTENSIN II-INDUCED VASCULAR REMODELING,
27th European Meeting on Hypertension and Cardiovascular Protection, Jun. 2017.
19. Yamazaki Risa, Fujita Tesuo, Yanagihara Madoka, Nakamura Hiroyuki, Hiromichi Fujino, Kasuya Yoshitoshi and Murayama Toshihiko :
Cyclosporin A has anti-fibrotic effects in human lung fibroblasts and in bleomycin-induced lung fibrosis model mice,
Annual Meeting of American Society for Pharmacology and Experimental Therapeutics (ASPET)-2016 (San Diego, USA), Apr. 2016.

Proceeding of Domestic Conference:

1. Masaki Imanishi, Takahisa Inoue, Keijo Fukushima, GOMI Yoshiki, HIGAKI Yoshiya, Masataka Nojima, Kohsuke Kondoh, SAWAMURA Takaya, Ryosuke Yamashita, Ryo Nakayama, Honoka Tsunematsu, GOTOH Kohei, Licht Miyamoto, Masafumi Funamoto, Hiromichi Fujino, Yasumasa Ikeda and Koichiro Tsuchiya :
TCGAがんゲノムビッグデータによる膵がん悪性化因子の網羅的探索と腫瘍血管新生の寄与についての検討,
第53回日本心脈管作動物質学会年会, Feb. 2024.
2. Honoka Tsunematsu, Masaki Imanishi, Yuka Uemura, HIGAKI Yoshiya, Keijo Fukushima, Miyu Morisaki, Akari Katsura, Licht Miyamoto, Masafumi Funamoto, Yuya Horinouchi, Yasumasa Ikeda, Hiromichi Fujino, Koichi Tsuneyama and Koichiro Tsuchiya :
藍含有成分はendothelin-1発現を制御して肺動脈血管リモデリングを形成させる,
次世代を担う若手のための創薬・医療薬理シンポジウム2023, Aug. 2023.
3. SAWAMURA Takaya, Masaki Imanishi, Keijo Fukushima, Ryosuke Yamashita, Kohsuke Kondoh, Ryo Nakayama, GOMI Yoshiki, Honoka Tsunematsu, Takahisa Inoue, GOTOH Kohei, Licht Miyamoto, Masafumi Funamoto, Hiromichi Fujino, Yasumasa Ikeda and Koichiro Tsuchiya :
PARP阻害剤は低酸素環境下において生じる5-FU治療効果の減弱を回復させる,
生体機能と創薬シンポジウム2023, Aug. 2023.
4. GOMI Yoshiki, Masaki Imanishi, Takahisa Inoue, Keijo Fukushima, Ryosuke Yamashita, Ryo Nakayama, Masataka Nojima, Kohsuke Kondoh, SAWAMURA Takaya, Honoka Tsunematsu, GOTOH Kohei, Licht Miyamoto, Masafumi Funamoto, Hiromichi Fujino, Yasumasa Ikeda and Koichiro Tsuchiya :
TCGAがんゲノムビッグデータとGEOトランスクリプトームデータとの統合解析による膵がん治療標的候補遺伝子の探索,
生体機能と創薬シンポジウム2023, Aug. 2023.
5. Mayu Yamashita, Hitomi Yamamoto, SHINOHARA Mayu, Keijo Fukushima, 菅波 晃子, 田村 裕 and Hiromichi Fujino :
PGJ2のヒトEP2プロスタノイド受容体を介したcAMP産生に対する影響,
日本薬学会 第143年会, Mar. 2023.
6. Yuki Nakano, Kiyoka Matsumoto, Ayaka Ohgimoto, SOMEYA Saki, Keijo Fukushima and Hiromichi Fujino :
EP4プロスタノイド受容体シグナルの代謝機構への影響,
日本薬学会 第143年会, Mar. 2023.
7. Haruka Okabayashi, Miki Yasuda, NII Chinatsu, Keijo Fukushima, 湯浅 浩気, 琴浦 聡 and Hiromichi Fujino :
プラズマローゲンによるアルツハイマー病発症予防メカニズムの解明,
日本薬学会 第143年会, Mar. 2023.
8. Miho Agata, Nanae Hasuoka, 間下 雅士, Keijo Fukushima and Hiromichi Fujino :
プロスタグランジンD2代謝物のCRTH2受容体を介した機能的差異の解明,
日本薬学会 第143年会, Mar. 2023.
9. Kohsuke Kondoh, Masaki Imanishi, Ryosuke Yamashita, Keijo Fukushima, Ryo Nakayama, Honoka Tsunematsu, Takahisa Inoue, GOTOH Kohei, Licht Miyamoto, Masafumi Funamoto, Hiromichi Fujino, Yasumasa Ikeda and Koichiro Tsuchiya :
5-FUの膵がん細胞増殖抑制効果に対する低酸素―PARP活性化シグナルの役割,
第262回徳島医学会学術集会(徳島), Feb. 2023.
10. Masaki Imanishi, 山下 竜介, Keijo Fukushima, 近藤 宏祐, 中山 涼, 常松 保乃加, 井上 貴久, 後藤 廣平, Masafumi Funamoto, Hiromichi Fujino, Yasumasa Ikeda and Koichiro Tsuchiya :
5-FU膵がん細胞増殖抑制効果に対する低酸素-PARPシグナルの役割,
第52回心脈管作動物質学会, Feb. 2023.
11. Keijo Fukushima and Hiromichi Fujino :
EP3プロスタノイド受容体サブタイプを高発現するヒト大腸がんクラスターの同定と性質評価,
第96回 日本薬理学会年会, Nov. 2022.
12. Takaya Misao, 北島 満里子, 村木 拓斗, 林 隼太郎, Kohki Takahashi, Keijo Fukushima, 北井 淳一郎, 奥村 明子, 吉田 博也, 石川 勇人 and Hiromichi Fujino :
パラグアイ原産ハーブCyclollepis genistoides D. Don(パロアッスル)の抗糖尿病生物活性成分含有画分の活性評価,
第96回 日本薬理学会年会, Nov. 2022.
13. 平岡 小波, 小林 愛花, Takaya Misao, 野村 篤生, 根本 滋, Hiromichi Fujino, 藤井 健志 and 間下 雅士 :
PARP1 依存的 EGFR のエンドサイトーシスによるがん細胞増殖シグナル抑制機構の解明,
第142回 日本薬理学会近畿部会, Nov. 2022.
14. 村嶋 優香, Yuya Horinouchi, 山田 佑人, 吉岡 駿, Keijo Fukushima, 久禮 匠, 佐々木 尚史, Hiromichi Fujino, 四宮 一昭 and Yasumasa Ikeda :
フィブラート系薬剤の腎保護効果に関する検討,
第61回 日本薬学会 中四国支部学術大会, Nov. 2022.
15. 山下 竜介, Masaki Imanishi, Keijo Fukushima, 近藤 宏祐, 中山 涼, 常松 保乃加, 井上 貴久, 後藤 廣平, Masafumi Funamoto, Hiromichi Fujino, Yasumasa Ikeda and Koichiro Tsuchiya :
低酸素がん微小環境におけるPARP活性化は5-FUによる膵がん細胞増殖抑制効果の減弱に寄与する,
第142回日本薬理学会近畿部会, Nov. 2022.
16. Keijo Fukushima and Hiromichi Fujino :
プロスタノイドEP2受容体とEP4受容体,
生体機能と創薬シンポジウム2022, Aug. 2022.
17. Hiromichi Fujino :
EP4プロスタノイド受容体とEP2プロスタノイド受容体,
第19回 生命科学研究会, Jul. 2022.
18. Takaya Misao, Keijo Fukushima and Hiromichi Fujino :
内因性カンナビノイドによる抗結腸がんメカニズムの解明,
第63回 日本生化学会 中国・四国支部例会, May 2022.
19. Haruka Kobayashi, Haruka Okabayashi, Miki Yasuda, Keijo Fukushima, 川村 純, 琴浦 聡 and Hiromichi Fujino :
アラキドン酸による神経毒生を緩和するプラズマローゲン作用の解明,
日本薬学会第142年会,名古屋, Mar. 2022.
20. Ayaka Hamaguchi, Keijo Fukushima, 福田 隼人, 藤原 広一, 周東 智 and Hiromichi Fujino :
Resolvin E-seriesの炎症収束作用の検討,
日本薬学会第142年会,名古屋, Mar. 2022.
21. Kanaho Senoh, Hitomi Yamamoto, Suzu Endoh, W John Regan, Keijo Fukushima and Hiromichi Fujino :
プロスタグランジンD2の代謝物はDPプロスタノイド受容体に対してバイアスアゴニストとして働く,
第95回日本薬理学会年会,福岡, Mar. 2022.
22. Akito Ohnishi, Akiko Higashiyama, Shunya Yanagawa, 清良 尚史, W John Regan, Kento Ohkawachi, Masaya Denda, Keijo Fukushima, Akira Otaka and Hiromichi Fujino :
プロスタノイドEP4受容体の1アミノ酸変異によるシグナル伝達プロファイル変化,
第95回日本薬理学会年会,福岡, Mar. 2022.
23. Yasumasa Ikeda, Hirofumi Hamano, Mitsuhiro Goda, Keijo Fukushima, Seiji Kishi, Masayuki Chuma, Yoshito Zamami, Licht Miyamoto, 石澤 啓介, Hiromichi Fujino, Ken-ichi Aihara, Koichiro Tsuchiya and Toshiaki Tamaki :
Identification of a candidate drug for the prevention of cisplatin-induced nephrotoxicity by a database analysis -basic research-clinical study,
第94回日本薬理学会年会, Mar. 2021.
24. Nanae Hasuoka, Miho Agata, 間下 雅士, Keijo Fukushima and Hiromichi Fujino :
PGD2およびその代謝物によるCRTH2受容体へのバイアス作用の解明,
日本薬学会第141年会, Mar. 2021.
25. Kiyoka Matsumoto, Yuki Nakano, 高橋 弘喜, 楠屋 陽子, 村山 俊彦, Keijo Fukushima and Hiromichi Fujino :
PGE2による結腸がん細胞内代謝変化の解析,
日本薬学会第141年会, Mar. 2021.
26. Harumi Takano, Kanaho Senoh, Mayu Yamashita, Yumi Araki, Regan John W, Keijo Fukushima and Hiromichi Fujino :
EP4プロスタノイド受容体を介したプロスタグランジンD2のバイアス性による抗癌作用,
第94回日本薬理学会年会, Mar. 2021.
27. Rei Matsumoto, Kaori Ueki, Yuta Masuda, 間下 雅士, Keijo Fukushima and Hiromichi Fujino :
結腸癌転移に関与するヒスタミンH1受容体作用の解明,
Mar. 2021.
28. Takaya Misao, Keijo Fukushima and Hiromichi Fujino :
内因性カンナビノイドによる抗結腸がんメカニズムの解明,
日本薬学会第141年会, 2021.
29. 森 愛実, 清水 未来華, Hiromichi Fujino and 間下 雅士 :
PARP14による大腸癌の増殖に関与するEP4受容体の発現調節機構の解明,
日本薬学会第140年会, Mar. 2020.
30. Manabu Sugiyama, Akito Ohnishi, Takuya Morisaki, Akira Shigenaga, Keijo Fukushima, Akira Otaka and Hiromichi Fujino :
inteinシステムを用いたプロスタノイドEP4受容体の局在解析を目指して,
日本薬学会第140年会, Mar. 2020.
31. Natsuki Yamagiwa, Haruka Kobayashi, Keijo Fukushima, Haruka Okabayashi, 川村 純, 琴浦 聡 and Hiromichi Fujino :
アラキドン酸による神経毒性作用を緩和する有効な生理活性脂質としてのプラズマローゲン種の同定,
日本薬学会第140年会, Mar. 2020.
32. Kana Kitagawa, Ayaka Hamaguchi, 間下 雅士, Regan John W., Keijo Fukushima and Hiromichi Fujino :
ヒト結腸がんHCA-7細胞においてインターロイキン4はEP4プロスタノイド受容体発現を抑制する,
第93回日本薬理学会年会, Mar. 2020.
33. Suzu Endoh, Kanaho Senoh, Harumi Takano, Yumi Araki, Regan John W., Keijo Fukushima and Hiromichi Fujino :
PGE2代謝物 15-keto-PGE2はバイアスアゴニストとしてEP2およびEP4プロスタノイド受容体に作用する,
第93回日本薬理学会年会, Mar. 2020.
34. Hirofumi Hamano, Yasumasa Ikeda, Mitsuhiro Goda, Keijo Fukushima, Seiji Kishi, Kenshi Takechi, Masayuki Chuma, Yoshito Zamami, Yuya Horinouchi, Licht Miyamoto, Hiromichi Fujino, Keisuke Ishizawa, Koichiro Tsuchiya and Toshiaki Tamaki :
シスプラチン誘発性腎障害を予防する既存薬物の同定,
第260回徳島医学会学術集会(令和元年度冬期), Feb. 2020.
35. Masayuki Chuma, Mitsuhiro Goda, Takahiro Niimura, Yoshito Zamami, Kenshi Takechi, Yuki Izawa-Ishizawa, 濱野 裕章, 石田 俊介, Takahiro Niimura, Masateru Kondoh, Takashi Bandoh, Naoto Okada, Keijo Fukushima, Hiromichi Fujino, Koichiro Tsuchiya, Yuya Horinouchi, Yasumasa Ikeda, Hiroaki Yanagawa and Keisuke Ishizawa :
ドラッグリポジショニング手法を用いたバンコマイシン関連腎障害の予防薬探索とその有用性の検討,
第13回日本腎臓病薬物療法学会学術集会・総会, Nov. 2019.
36. Yuta Masuda, Kiyoka Matsumoto, Rei Matsumoto, Keijo Fukushima and Hiromichi Fujino :
抗ヒスタミン薬による大腸がん誘発への有害事象の検討,
第26回日本免疫毒性学会学術年会, Jul. 2019.
37. 新村 貴博, Yoshito Zamami, Yuki Izawa-Ishizawa, Mitsuhiro Goda, Kenshi Takechi, Masayuki Chuma, Keijo Fukushima, Yuya Horinouchi, Yasumasa Ikeda, Hiromichi Fujino, Koichiro Tsuchiya and Keisuke Ishizawa :
大規模医療情報を用いたニコランジルの心肺停止後予後改善効果の検討,
医療薬学フォーラム2019/第27回クリニカルファーマシーシンポジウム, Jul. 2019.
38. Mitsuhiro Goda, 斉家 和仁, Akiko Maegawa, Masaya Kanda, Ami Yoshida, Yoichi Murai, Takahiro Niimura, Yuki Izawa-Ishizawa, Yoshito Zamami, Masayuki Chuma, Kenshi Takechi, Hirofumi Hamano, Naoto Okada, Keijo Fukushima, Hiromichi Fujino, Koichiro Tsuchiya, Yuya Horinouchi, Yasumasa Ikeda, Hiroaki Yanagawa and Keisuke Ishizawa :
医療ビッグデータを活用したシスプラチン誘発腎障害に対する新規予防薬の探索とその有効性の検証,
第4回中四国臨床薬理学会, Jul. 2019.
39. Hiromichi Fujino :
大腸の恒常性維持および癌発症とEP4受容体発現調節機構,
第18回 生命科学研究会, Jun. 2019.
40. Takahiro Niimura, Yoshito Zamami, Yuki Izawa-Ishizawa, Mitsuhiro Goda, Kenshi Takechi, Masayuki Chuma, Keijo Fukushima, Yuya Horinouchi, Yasumasa Ikeda, Hiromichi Fujino, Koichiro Tsuchiya and Keisuke Ishizawa :
医療ビッグデータ解析と基礎研究を融合した薬剤性副作用の機序解明および治療薬の開発,
第29回日本医療薬学会年会 シンポジウム13, Mar. 2019.
41. 近藤 正輝, Masaki Imanishi, Keijo Fukushima, Yuya Horinouchi, Yuki Izawa-Ishizawa, Yuki Izawa-Ishizawa, Mitsuhiro Goda, Yoshito Zamami, Kenshi Takechi, Masayuki Chuma, Yasumasa Ikeda, Hiromichi Fujino, Koichiro Tsuchiya and Keisuke Ishizawa :
キサンチンオキシダーゼ阻害剤による新規血管線維化抑制機構の検討,
日本薬学会第139年会 大学院生シンポジウムGS03, Mar. 2019.
42. Yuya Horinouchi, Yasumasa Ikeda, Hirofumi Hamano, Masaki Imanishi, Keijo Fukushima, Mitsuhiro Goda, Kenshi Takechi, Licht Miyamoto, Yuki Izawa-Ishizawa, Yoshito Zamami, Hiromichi Fujino, Keisuke Ishizawa, Koichiro Tsuchiya and Toshiaki Tamaki :
慢性腎不全関連骨格筋萎縮における鉄代謝異常,
第92回日本薬理学会年会, Mar. 2019.
43. 山形 一行, 清良 尚史, 福島 圭稔, Yumi Araki, 倉田 直希, 柳澤 直樹, 間下 雅士, 中村 浩之, W John Regan, 村山 俊彦 and Hiromichi Fujino :
HIF-1α and c-Myc oppositely regulate human EP4 receptor promoter activity in human colon cancer HCA-7 cells,
第92回日本薬理学会年会, Mar. 2019.
44. Takahiro Niimura, Yoshito Zamami, Yuki Izawa-Ishizawa, Hiroumi Saito, Masaki Imanishi, Kenshi Takechi, Masayuki Chuma, Keijo Fukushima, Yuya Horinouchi, Yasumasa Ikeda, Hiromichi Fujino, Koichiro Tsuchiya and Keisuke Ishizawa :
大規模医療情報データベースおよび遺伝子発現データベースを活用した薬剤性心筋炎に対する予防薬の探索,
第28回日本医療薬学会年会 シンポジウム, Nov. 2018.
45. Yuya Horinouchi, Yasumasa Ikeda, Keijo Fukushima, Hirofumi Hamano, Masaki Imanishi, Yuki Izawa-Ishizawa, Yoshito Zamami, Kenshi Takechi, Hiromichi Fujino, Keisuke Ishizawa, Koichiro Tsuchiya and Toshiaki Tamaki :
リアルワールドビッグデータを活用した新規腎保護薬の探索,
第28回日本医療薬学会年会, Nov. 2018.
46. Kohei Nishida, 水口 博之, Tomohiro Nakano, 北村 紀子, 内田 勝幸, 神沼 修, Hiromichi Fujino and 福井 裕行 :
阿波番茶由来 NFAT シグナル抑制化合物の同定とその標的分子の探索,
第134回日本薬理学会近畿部会, Nov. 2018.
47. Yuya Horinouchi, Yasumasa Ikeda, Hirofumi Hamano, Masaki Imanishi, Keijo Fukushima, Mitsuhiro Goda, Kenshi Takechi, Licht Miyamoto, Yuki Izawa-Ishizawa, Yoshito Zamami, Hiromichi Fujino, Keisuke Ishizawa, Koichiro Tsuchiya and Toshiaki Tamaki :
慢性腎不全関連サルコペニアにおける鉄の関与,
第134回日本薬理学会近畿部会, Nov. 2018.
48. 生藤 来希, Masaki Imanishi, 山川 祐介, Keijo Fukushima, 前川 晃子, Yuya Horinouchi, Yuki Izawa-Ishizawa, Mitsuhiro Goda, Yoshito Zamami, Kenshi Takechi, Masayuki Chuma, Yasumasa Ikeda, Hiromichi Fujino and Koichiro Tsuchiya :
大腸がん増大におけるがん関連線維芽細胞由来ERKSの役割,
第57回日本薬学会・日本薬剤師会・日本病院薬剤師会 中国四国支部学術大会, Nov. 2018.
49. Yuya Horinouchi, Yasumasa Ikeda, Keijo Fukushima, Yuki Izawa-Ishizawa, Hiromichi Fujino and Toshiaki Tamaki :
リアルワールドデータを活用した新規腎保護薬の探索,
第48回日本腎臓学会西部学術大会, Sep. 2018.
50. 新村 貴博, Yoshito Zamami, Yuki Izawa-Ishizawa, Mitsuhiro Goda, Masaki Imanishi, Kenshi Takechi, Keijo Fukushima, Yuya Horinouchi, Yasumasa Ikeda, Hiromichi Fujino, Koichiro Tsuchiya and Keisuke Ishizawa :
大規模医療情報を活用した新規心肺蘇生後脳症治療薬の探索,
第29回霧島神経薬理フォーラム, Aug. 2018.
51. Masaki Imanishi, Masateru Kondoh, 山川 裕介, 生藤 来希, 村井 陽一, Yoshito Zamami, Kenshi Takechi, Masayuki Chuma, Yuya Horinouchi, Keijo Fukushima, Yuki Izawa-Ishizawa, Yasumasa Ikeda, Hiromichi Fujino, Koichiro Tsuchiya and Keisuke Ishizawa :
Angiotensin II誘発性心臓線維化は線維芽細胞特異的ERK5欠損マウスにおいて亢進される,
第133回日本薬理学会近畿部会, Jun. 2018.
52. Yoshito Zamami, Marin Mitsui, Yuki Izawa-Ishizawa, Kenshi Takechi, Masaki Imanishi, Yuya Horinouchi, Keijo Fukushima, Yasumasa Ikeda, Hiromichi Fujino, Koichiro Tsuchiya, Toshiaki Tamaki and Keisuke Ishizawa :
有害事象自発報告データベースを活用したベバシズマブの抗腫瘍効果を減弱させる薬剤の探索研究,
日本薬学会第138年会, Mar. 2018.
53. Takahiro Niimura, Yoshito Zamami, Yuki Izawa-Ishizawa, Masaki Imanishi, Kenshi Takechi, Keijo Fukushima, Yuya Horinouchi, Yasumasa Ikeda, Hiromichi Fujino, Koichiro Tsuchiya, Toshiaki Tamaki and Keisuke Ishizawa :
ドラッグリポジショニング手法を用いた心肺蘇生後脳症治療薬の探索,
日本薬学会第138年会, Mar. 2018.
54. Tomoharu Wakugawa, 水口 博之, Miharu Hiramatsu, 永峰 賢一, 田辺 英矢, 篠原 啓子, 沢田 英司, Hiromichi Fujino, 福井 裕行 and 武田 憲昭 :
レンコン由来の抗アレルギー成分の単離,
日本薬学会第138年会, Mar. 2018.
55. Natsumi Tokashiki, Naoki Kurata, Takaya Misao, Yumi Araki, 清良 尚史, Natsuki Yamagiwa, Manabu Sugiyama, Keijo Fukushima, W John REGAN, 村山 俊彦 and Hiromichi Fujino :
ヒト結腸がんHCA-7 細胞における酪酸によるEP4 受容体発現系への影響,
日本薬学会第138年会, Mar. 2018.
56. Keijo Fukushima, 市川 和哉, 上野 崇宏, 稲垣 孝行, 宮川 泰宏, 千﨑 康司, Hiromichi Fujino and 山田 清文 :
関節リウマチ治療薬を対象とした有害事象自発報告データベースFAERSを用いた感染症リスクの比較,
第256回徳島医学会学術集会, Feb. 2018.
57. Yuya Horinouchi, Yasumasa Ikeda, Keijo Fukushima, Hirofumi Hamano, Masaki Imanishi, Yuki Izawa-Ishizawa, Yoshito Zamami, Hiromichi Fujino, Keisuke Ishizawa, Koichiro Tsuchiya and Toshiaki Tamaki :
大規模医療情報データベース解析と基礎研究の融合による新規腎保護薬の探索,
第256回 徳島医学会学術集会(平成29年度冬期), Feb. 2018.
58. Masaki Imanishi, Masateru Kondoh, Kyohei Tanaka, Raiki Ikutoh, Yoichi Murai, Yoshito Zamami, Kenshi Takechi, Yuya Horinouchi, Yuki Izawa-Ishizawa, Yasumasa Ikeda, Hiromichi Fujino, Koichiro Tsuchiya, Toshiaki Tamaki and Keisuke Ishizawa :
Febuxostatの尿酸合成抑制作用とは独立した血管線維化抑制機構の解明,
第256回 徳島医学会学術集会(平成29年度冬期), Feb. 2018.
59. Takahiro Niimura, Yoshito Zamami, Yuki Izawa-Ishizawa, Masaki Imanishi, Kenshi Takechi, Keijo Fukushima, Yuya Horinouchi, Yasumasa Ikeda, Hiromichi Fujino, Koichiro Tsuchiya, Toshiaki Tamaki and Keisuke Ishizawa :
大規模医療情報を活用した心肺停止患者に対するニコランジルの有効性に関する検討,
第256回 徳島医学会学術集会(平成29年度冬期), Feb. 2018.
60. Yuya Horinouchi, Yasumasa Ikeda, Keijo Fukushima, Masaki Imanishi, Yuki Izawa-Ishizawa, Yoshito Zamami, Hiromichi Fujino, Keisuke Ishizawa, Koichiro Tsuchiya and Toshiaki Tamaki :
第Xa因子阻害剤の腎保護効果,
第47回日本心脈管作動物質学会, Feb. 2018.
61. Yuya Horinouchi, Yasumasa Ikeda, Keijo Fukushima, Yuki Izawa-Ishizawa, Hiromichi Fujino and Toshiaki Tamaki :
医療ビッグデータを活用した腎保護薬の探索,
2017年度 肥満・糖尿病クラスター・ミニリトリート, Feb. 2018.
62. Yuya Horinouchi, Yasumasa Ikeda, Keijo Fukushima, Masaki Imanishi, Yuki Izawa-Ishizawa, Yoshito Zamami, Hiromichi Fujino, Keisuke Ishizawa, Koichiro Tsuchiya and Toshiaki Tamaki :
第Xa因子阻害薬の腎保護効果,
第10回 心・血管クラスター・ミニリトリート, 2017.
63. Akiho Sawada, 水口 博之, 武田 憲昭, Hiromichi Fujino and 福井 裕行 :
トラニラストに見出された新規アレルギー抑制機構,
第21回日本ヒスタミン学会, Dec. 2017.
64. 水口 博之, Tomohiro Nakano, Kohei Nishida, 北村 紀子, 内田 勝幸, Hiromichi Fujino, 神沼 修 and 福井 裕行 :
阿波晩茶に見出された新規NFATシグナル抑制化合物の同定とその作用機序,
2017年度生命科学系合同年次大会, Dec. 2017.
65. Takahiro Niimura, Yoshito Zamami, Yuki Izawa-Ishizawa, Masaki Imanishi, Kenshi Takechi, Keijo Fukushima, Yuya Horinouchi, Yasumasa Ikeda, Hiromichi Fujino, Koichiro Tsuchiya, Toshiaki Tamaki and Keisuke Ishizawa :
大規模医療情報を用いて新規心肺蘇生後症候群治療薬の開発を志向したドラッグリポジショニング研究,
第38回日本臨床薬理学会学術総会, Dec. 2017.
66. Yoshito Zamami, Yuki Izawa-Ishizawa, Takahiro Niimura, Kenshi Takechi, Masaki Imanishi, Yuya Horinouchi, Yasumasa Ikeda, Hiromichi Fujino, Koichiro Tsuchiya, Toshiaki Tamaki and Keisuke Ishizawa :
臨床薬理学集中講座修了後の研究活動∼大規模医療情報を活用したドラッグリポジショニング研究を中心に∼,
第38回日本臨床薬理学会学術総会 臨床薬理学集中講座フォローアップ・セミナー, Dec. 2017.
67. Natsuki Okajima, 水口 博之, Ayumi Kiyuta, 河井 真季子, 北村 嘉章, 武田 憲昭, Hiromichi Fujino and 福井 裕行 :
苦参由来抗アレルギー化合物(-)マーキアインのステロイドシグナルへの影響,
第132回日本薬理学会近畿部会, Nov. 2017.
68. 浪花 志帆, 水口 博之, Yuki Konishi, 北村 嘉章, 武田 憲昭, Hiromichi Fujino and 福井 裕行 :
小青竜湯によるアレルギー性鼻炎疾患感受性遺伝子発現抑制,
第132回日本薬理学会近畿部会, Nov. 2017.
69. Takahiro Niimura, Yoshito Zamami, 小山 敏広, Kenshi Takechi, Masaki Imanishi, Yuya Horinouchi, Yuki Izawa-Ishizawa, Yasumasa Ikeda, Hiromichi Fujino, Koichiro Tsuchiya, Toshiaki Tamaki and Keisuke Ishizawa :
ドラッグリポジショニングを切り口とした心肺蘇生後症候群治療薬の探索研究,
第27回日本医療薬学会年会, Nov. 2017.
70. Yoshito Zamami, 小山 敏広, Yuki Izawa-Ishizawa, Takahiro Niimura, Masaki Imanishi, Kenshi Takechi, Yuya Horinouchi, 桐野 靖, 中村 敏己, 寺岡 和彦, Yasumasa Ikeda, Hiromichi Fujino, Koichiro Tsuchiya, Toshiaki Tamaki and Keisuke Ishizawa :
大規模医療情報を活用して心肺停止患者の生存率向上を志向したドラッグリポジショニング研究,
第27回日本医療薬学会年会, Nov. 2017.
71. Marin Mitsui, Yoshito Zamami, Yuki Izawa-Ishizawa, Takahiro Niimura, Kenshi Takechi, Masaki Imanishi, Keijo Fukushima, Yuya Horinouchi, Yasumasa Ikeda, Hiromichi Fujino, Koichiro Tsuchiya, Toshiaki Tamaki and Keisuke Ishizawa :
有害事象自発報告データベースを基にしたベバシズマブと相互作用を起こす薬剤の探索研究,
第56回日本薬学会・日本薬剤師会・日本病院薬剤師会 中国四国支部学術大会, Oct. 2017.
72. Takahiro Niimura, Yoshito Zamami, Yuki Izawa-Ishizawa, Masaki Imanishi, Kenshi Takechi, Keijo Fukushima, Yuya Horinouchi, Yasumasa Ikeda, Hiromichi Fujino, Koichiro Tsuchiya, Toshiaki Tamaki and Keisuke Ishizawa :
心肺停止患者の予後に与えるニコランジルの影響-大規模レセプト情報を用いた検討,
第56回日本薬学会・日本薬剤師会・日本病院薬剤師会 中国四国支部学術大会, Oct. 2017.
73. Shiori Urushizaki, Yoshito Zamami, Yuki Izawa-Ishizawa, Takahiro Niimura, Kenshi Takechi, Masaki Imanishi, Keijo Fukushima, Yuya Horinouchi, Yasumasa Ikeda, Hiromichi Fujino, Koichiro Tsuchiya, Toshiaki Tamaki and Keisuke Ishizawa :
大規模医療情報を活用して新規心肺蘇生後症候群治療薬の開発を志向したドラッグリポジショニング研究,
第56回日本薬学会・日本薬剤師会・日本病院薬剤師会 中国四国支部学術大会, Oct. 2017.
74. Rezwanul Isram, Aurpita Shaha, Kentaroh Okamoto, Tomoharu Wakugawa, Miharu Hiramatsu, 池田 久, Hiromichi Fujino, 福井 裕行 and 水口 博之 :
Wild grapes suppress the histamine H1 receptor gene expression in HeLa cells and in TDI-sensitized allergy model rats,
第56回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会, Oct. 2017.
75. Kentaroh Okamoto, 水口 博之, 藤井 達也, Manabu Sugiyama, 北山 美香, 山田 拓也, 大谷 将太郎, 神村 盛一郎, 北村 嘉章, Hiromichi Fujino, 福井 裕行 and 武田 憲昭 :
ナローバンドUVBによるアレルギー性鼻炎抑制効果,
第56回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会, Oct. 2017.
76. 荒木 祐美, 菅波 晃子, Suzu Endoh, Hiroyuki Mizuguchi, Keijo Fukushima, W John REGAN, 村山 俊彦, 田村 裕 and Hiromichi Fujino :
PGE1とPGE3のバイアス性と癌抑制機構の解明,
第56回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会, Oct. 2017.
77. Kyohei Tanaka, Masaki Imanishi, Masateru Kondoh, Raiki Ikutoh, Yoichi Murai, Yoshito Zamami, Kenshi Takechi, Yuya Horinouchi, Yuki Izawa-Ishizawa, Yasumasa Ikeda, Hiromichi Fujino, Koichiro Tsuchiya, Toshiaki Tamaki and Keisuke Ishizawa :
フェブキソスタットの尿酸合成抑制剤作用とは独立した血管線維化抑制作用の検討,
第56回日本薬学会・日本薬剤師会・日本病院薬剤師会 中国四国支部学術大会, Oct. 2017.
78. Takeyasu Ogasawara, 水口 博之, Ayumi Kiyuta, 河井 真季子, Natsuki Okajima, Hiromichi Fujino, 北村 嘉章, 武田 憲昭 and 福井 裕行 :
苦参由来抗アレルギー化合物(-)マーキアインのステロイドシグナル増強作用,
第34回 和漢医薬学会, Aug. 2017.
79. Takahiro Niimura, Yoshito Zamami, Yuki Izawa-Ishizawa, Masaki Imanishi, Kenshi Takechi, Keijo Fukushima, Yuya Horinouchi, Yasumasa Ikeda, Hiromichi Fujino, Koichiro Tsuchiya, Toshiaki Tamaki and Keisuke Ishizawa :
心肺蘇生後症候群治療薬の開発を目的としたドラッグリポジショニング研究-大規模医療情報を活用した検討-,
第255回 徳島医学会学術集会, Aug. 2017.
80. Yoshito Zamami, Yuki Izawa-Ishizawa, 桐野 靖, Marin Mitsui, Shiori Urushizaki, Kenshi Takechi, Masaki Imanishi, Yuya Horinouchi, Yasumasa Ikeda, Hiromichi Fujino, Koichiro Tsuchiya, Toshiaki Tamaki and Keisuke Ishizawa :
有害事象自発報告データベースを切り口としたベバシズマブの抗腫瘍効果を減弱させる薬剤の探索研究,
医療薬学フォーラム2017 第25回クリニカルファーマシーシンポジウム, Jul. 2017.
81. Tomoharu Wakugawa, Miharu Hiramatsu, 永峰 賢一, 田辺 英矢, 篠原 啓子, 沢田 英司, Hiromichi Fujino, Hiroyuki Fukui and Hiroyuki Mizuguchi :
レンコンに含まれる花粉症発症抑制成分の単離,
第131回日本薬理学会近畿部会(名古屋), Jun. 2017.
82. Marin Mitsui, Yoshito Zamami, Yuki Izawa-Ishizawa, Shiori Urushizaki, 桐野 靖, Kazuhito Saike, Hiroshi Moriguchi, Kenshi Takechi, Masaki Imanishi, Yuya Horinouchi, Yasumasa Ikeda, Hiromichi Fujino, Koichiro Tsuchiya, Toshiaki Tamaki and Keisuke Ishizawa :
有害事象自発報告データベースを基にしたベバシズマブの抗腫瘍効果を減弱させる薬剤の探索研究,
日本薬学会 第137年会, Mar. 2017.
83. Raiki Ikutoh, Masaki Imanishi, Kyohei Tanaka, Yoshito Zamami, Kenshi Takechi, Yuya Horinouchi, Yuki Izawa-Ishizawa, Yasumasa Ikeda, Hiromichi Fujino, Koichiro Tsuchiya, Toshiaki Tamaki and Keisuke Ishizawa :
アンジオテンシンII 誘発性血管リモデリングに対するキサンチンオキシダーゼ阻害剤の影響,
日本薬学会 第137年会, Mar. 2017.
84. Kiyotake Yamamoto, Hiroyuki Mizuguchi, 渡嘉敷 夏海, 小林 誠, Youichi Sato, Hiromichi Fujino, Hiroyuki Fukui and Aiko Yamauchi :
膵α細胞からのグルカゴン分泌に関与するPKCアイソザイムの同定,
日本薬学会第137年会, Mar. 2017.
85. 荒木 祐美, Hiromichi Fujino, 菅波 晃子, Hiroyuki Mizuguchi, Regan W. John, 遠藤 すず, 田村 裕 and 村山 俊彦 :
ヒトEP4プロスタノイド受容体におけるPGEシリーズのバイアス性,
日本薬学会第137年会, Mar. 2017.
86. 清良 尚史, Hiromichi Fujino, 大竹 翔, Regan W. John, 高橋 弘喜 and 村山 俊彦 :
ヒト結腸癌HCA-7細胞株におけるEP4受容体発現制御機構へのHIF-1αおよびPARP14発現の関与の解明,
日本薬学会第137年会, Mar. 2017.
87. Masaki Imanishi, Kyohei Tanaka, Raiki Ikuto, Yoshito Zamami, Kenshi Takechi, Yuya Horinouchi, Yuki Izawa-Ishizawa, Yasumasa Ikeda, Hiromichi Fujino, Koichiro Tsuchiya, Toshiaki Tamaki and Keisuke Ishizawa :
Febuxostat suppresses angiotensin II-induced aortic fibrosis,
第90回日本薬理学会年会, Mar. 2017.
88. Masaki Imanishi, 田中 恭平, 生藤 来希, Yoshito Zamami, Kenshi Takechi, Yuya Horinouchi, Yuki Izawa-Ishizawa, Yasumasa Ikeda, Hiromichi Fujino, Koichiro Tsuchiya, Toshiaki Tamaki and Keisuke Ishizawa :
フェブキソスタットはアンジオテンシンII誘発性大動脈繊維化を抑制する,
第90回日本薬理学会年会(長崎), Mar. 2017.
89. 伊藤 智平, Hiroyuki Mizuguchi, 中野 友寛, 西田 浩平, 北村 紀子, 神沼 修, 内田 勝幸, Hiromichi Fujino and Hiroyuki Fukui :
阿波番茶由来ピロガロールはカルシニューリン/NFATシグナルを抑制する,
第90回日本薬理学会年会(長崎), Mar. 2017.
90. Hiromichi Fujino, 菅波 晃子, 大蔵 伊織, 柳澤 直樹, 杉山 肇, Regan W. John, Hiroyuki Mizuguchi, 田村 裕 and 村山 俊彦 :
ヒトDPおよびEP2プロスタノイド受容体は個別のリガンドの異なる結合様式により独自のコンフォメーションを取りうる,
第90回日本薬理学会年会(長崎), Mar. 2017.
91. Yoshito Zamami, Yuki Izawa-Ishizawa, 桐野 靖, 三井 茉綸, 漆崎 汐里, 斉家 和仁, 森口 浩史, Kenshi Takechi, Masaki Imanishi, Yuya Horinouchi, Yasumasa Ikeda, Hiromichi Fujino, Koichiro Tsuchiya, Toshiaki Tamaki and Keisuke Ishizawa :
有害事象自発報告データベースを切り口としたベバシズマブと相互作用を起こす薬剤の探索研究,
第46回日本心脈管作動物質学会年会, Feb. 2017.
92. Masaki Imanishi, 田中 恭平, 生藤 来希, Yoshito Zamami, Kenshi Takechi, Yuya Horinouchi, Yuki Izawa-Ishizawa, Yasumasa Ikeda, Hiromichi Fujino, Koichiro Tsuchiya, Toshiaki Tamaki and Keisuke Ishizawa :
Angiotensin II誘発性血管リモデリングに対するfebuxostatの効果,
第46回日本心脈管作動物質学会, Feb. 2017.
93. Hiromichi Fujino :
DP受容体とEP2受容体: 分岐したプロスタノイド受容体の今,
第136回日本薬学会中国四国支部例会(徳島), Jan. 2017.
94. 中野 友寛, Hiroyuki Mizuguchi, 伊藤 智平, 北村 紀子, 神沼 修, 内田 勝幸, Hiromichi Fujino and Hiroyuki Fukui :
阿波番茶に見出された抗アレルギー成分ピロガロールのNFATシグナル抑制機構,
第20回日本ヒスタミン学会(倉敷), Nov. 2016.
95. 江洲 貴子, Hiroyuki Mizuguchi, 浪花 志帆, 小西 由貴, Yoshiaki Kitamura, Noriaki Takeda, Hiromichi Fujino and Hiroyuki Fukui :
小青龍湯によるアレルギー性鼻炎疾患感受性遺伝子発現抑制,
第20回日本ヒスタミン学会(倉敷), Nov. 2016.
96. 小笠原 健泰, Hiroyuki Mizuguchi, 給田 愛結美, 河井 真季子, 岡島 菜津希, Yoshiaki Kitamura, Noriaki Takeda, Hiromichi Fujino and Hiroyuki Fukui :
苦参由来抗アレルギー化合物(-)マーキアインのステロイドシグナルへの影響,
第130回日本薬理学会近畿部会(京都), Nov. 2016.
97. 古南 隆光, Hiroyuki Mizuguchi, 門田 卓也, 澤田 明歩, Yoshiaki Kitamura, Noriaki Takeda, Hiromichi Fujino and Hiroyuki Fukui :
スプラタストによるNFATシグナルを介した鼻過敏症症状改善効果,
第55回日本薬学会・日本薬剤師会・日本薬剤師会中国四国支部大会(岡山), Nov. 2016.
98. 岡本 健太郎, Hiroyuki Mizuguchi, 藤井 達也, 北山 美香, 山田 拓也, Yoshiaki Kitamura, Noriaki Takeda, Hiromichi Fujino and Hiroyuki Fukui :
ナローバンドUVBのヒスタミンH1受容体遺伝子発現への影響,
2016感染・免疫クラスター・ミニリトリート(徳島), Oct. 2016.
99. 清良 尚史, Hiromichi Fujino, 大竹 翔, Regan W. John and 村山 俊彦 :
転写因子低酸素誘導因子-1αによるヒトEP4受容体発現制御機構の解明,
第135回日本薬理学会関東部会(浜松), Oct. 2016.
100. 三井 茉綸, Yoshito Zamami, 漆崎 汐里, 斉家 和仁, 森口 浩史, Kenshi Takechi, Masaki Imanishi, Yuya Horinouchi, Licht Miyamoto, Yuki Izawa-Ishizawa, Yasumasa Ikeda, Hiromichi Fujino, Koichiro Tsuchiya, Toshiaki Tamaki and Keisuke Ishizawa :
ドラッグリポジショニングを切り口としたベバシズマブ誘発高血圧に対する予防薬の探索研究,
第27回霧島神経薬理フォーラム(福岡), Aug. 2016.
101. Hiromichi Fujino :
プロスタノイド受容体と癌,
第2回徳島大学薬学部若手教員講演会, Jun. 2016.
102. 清良 尚史, Hiromichi Fujino, 大竹 翔, Regan W. John and 村山 俊彦 :
ヒト結腸癌HCA-7細胞において,HIF-1α はEP4受容体プロモーターHRE配列に結合し,受容体発現を制御する,
日本薬学会第136年会(横浜), Mar. 2016.
103. 山崎 璃沙, 藤田 哲雄, 柳原 まどか, 中村 浩之, Hiromichi Fujino, 粕谷 善俊 and 村山 俊彦 :
シクロスポリンAはヒト肺線維芽細胞および肺線維症モデルマウスにおいて繊維化抑制作用を示す,
日本薬学会第136年会(横浜), Mar. 2016.
104. 柳沢 直樹, Hiromichi Fujino, 和才 真希子, 荒井 孝義 and 村山 俊彦 :
新規インドール化合物のヒト結腸がんLS174T細胞への抗がん作用の探索,
第89回日本薬理学会年会(横浜), Mar. 2016.
105. 谷本 淳, Hiromichi Fujino, 樋坂 章博, 高橋 弘喜 and 村山 俊彦 :
ヒトDPおよびEP2プロスタノイド受容体のcDNA配列変異の解析,
第89回日本薬理学会年会(横浜), Mar. 2016.

Et cetera, Workshop:

1. Hiromichi Fujino and Naonobu Tanaka :
国際交流「東國大学校薬学大学(韓国)との学術交流」,
薬学部だより, Vol.24, 4, Jul. 2019.
2. Hiromichi Fujino :
北から南から「徳島大学大学院医歯薬学研究部 薬学系 生命薬理学分野」,
Seikagaku, Vol.6, No.90, 842-843, 2018.
3. Hiromichi Fujino :
Knocking up? nahhh, thinking through, maybe...,
第34回 蔵本祭パンフレット, 115-116, Oct. 2018.
4. Hiromichi Fujino :
薬と毒と作用機序,
第33回 蔵本祭パンフレット, 115-116, Oct. 2017.

Report:

1. Yoshihiko Ueno, Yosuke Seki, Chigusa Uchiumi, Takeshi Iwasa, Akira Takahashi, Toshiyuki Yasui, Shinji Kawahito, Kazumi Ozaki, Hiromichi Fujino, Toshio Takayanagi, Takefumi Hattori, Takahito Saito and Maiko Kamioka :
令和5年度 徳島大学高等教育研究センターアドミッション部門 報告書,
令和5年度 徳島大学高等教育研究センターアドミッション部門 報告書, Mar. 2024.
2. Hiromichi Fujino :
インドメタシンの新たな抗癌機構の解明 : シクロオキシゲナーゼ阻害非依存的作用の探究.,
Chiba Medical Journal, Vol.86, 251, 2010.

Patent:

1. 荒井 孝義, Hiromichi Fujino, 村山 俊彦, 大山 聡美 and 阿波田 篤子 : -DPDP, (Sep. 2013), (Sep. 2013), 2013-192422 (Sep. 2013).

Grants-in-Aid for Scientific Research (KAKEN Grants Database @ NII.ac.jp)

  • プロスタノイドEP4受容体の恒常的活性による細胞増殖速度調整メカニズムの解明 (Project/Area Number: 23K06149 )
  • Explore the irreversible check point from normal to malignant transformation of the cells by changing in the balance of the expression levels of the EP prostanoid receptor subtypes. (Project/Area Number: 20K07084 )
  • Exploring the mechanism of EP4 prostanoid receptor-evoked colorectal cancer development during the collapse of homeostasis and its ameliorating effects by substances of type 2 innate immune system (Project/Area Number: 17K08308 )
  • Mechanisms of colon cancer malignancy regulation by two endogenous prostanoid receptors (Project/Area Number: 25460091 )
  • Exploring the novel cycloocygenase-inhibition-independent effects of indomethacin (Project/Area Number: 22590079 )
  • プロスタグランジンE2およびそのEP4受容体情報伝達系のガン化への関与の解明 (Project/Area Number: 18790045 )
  • Search by Researcher Number (40401004)